Bloom syndrome

Bloom syndrome
Name	Bloom syndrome
Symptoms	Short stature; photosensitivity; telangiectatic erythema; recurrent infections
Complications	Cancer; chronic lung disease; diabetes mellitus; infertility
Onset	Infancy or childhood
Causes	Biallelic mutations in BLM (RecQ helicase) gene
Diagnosis	Chromosomal breakage testing; genetic sequencing
Treatment	Supportive care; cancer surveillance; infection management
Frequency	Rare; higher in Ashkenazi Jewish population

Bloom syndrome is a rare autosomal recessive genetic disorder characterized by short stature, photosensitive skin changes, genomic instability, and a markedly increased predisposition to a wide spectrum of malignancies. First delineated by David Bloom in the 1950s, it arises from pathogenic variants in a RecQ family helicase and presents with recurrent infections and endocrinopathies in addition to dermatologic findings. Management focuses on surveillance for cancer, prevention of ultraviolet exposure, and multidisciplinary supportive care involving specialists in oncology, pulmonology, and endocrinology.

Signs and symptoms

Affected individuals typically demonstrate pre- and postnatal growth failure resulting in marked short stature, often prompting evaluation by pediatricians and tertiary care centers. Cutaneous findings include a photosensitive telangiectatic erythema resembling findings seen in patients following exposure during events like the Chernobyl disaster or in autosomal disorders described in studies from St. Bartholomew's Hospital. Recurrent sinopulmonary infections lead to chronic lung disease necessitating care at institutions such as Great Ormond Street Hospital or clinics following protocols from Centers for Disease Control and Prevention. Endocrine abnormalities include insulin resistance and diabetes mellitus managed per guidelines from the American Diabetes Association. Infertility, particularly male azoospermia and female diminished ovarian reserve, requires referral to reproductive endocrinology programs exemplified by services at Mayo Clinic or Johns Hopkins Hospital. Hematologic manifestations and early-onset malignancies overlap with cases treated at oncology centers like MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.

Genetics and molecular biology

The disorder is caused by biallelic pathogenic variants in the BLM gene, a member of the RecQ helicase family originally characterized by teams affiliated with Cold Spring Harbor Laboratory and National Institutes of Health. BLM encodes a 3' to 5' DNA helicase that collaborates with proteins from the RAD51-mediated homologous recombination pathway and interacts with complexes studied at European Molecular Biology Laboratory and Max Planck Institute. Loss of BLM function produces elevated sister chromatid exchanges and chromosomal rearrangements analogous to instability observed in disorders cataloged by Human Genome Variation Society and in cell models developed at Broad Institute. Molecular studies using CRISPR systems pioneered at Broad Institute and University of California, Berkeley have modeled BLM deficiency, revealing defective replication fork restart and increased micronuclei formation described in publications from Nature and Cell. Founder mutations in specific populations, notably variants traced through genealogical research involving archives such as those at Yad Vashem and population studies reported by Tel Aviv University, account for higher prevalence among individuals of Ashkenazi Jewish descent.

Diagnosis

Clinical suspicion prompts cytogenetic analysis demonstrating characteristic chromosomal breakage and elevated rates of sister chromatid exchange, techniques refined in laboratories at Royal Marsden Hospital and Guy's and St Thomas' NHS Foundation Trust. Definitive diagnosis is established by sequencing of BLM through platforms provided by commercial laboratories associated with Invitae and research sequencing centers like Wellcome Sanger Institute. Newborn screening is not routine; instead, diagnostic pathways follow algorithms from pediatric genetics clinics at Great Ormond Street Hospital and adult genetics programs at Massachusetts General Hospital. Prenatal diagnosis and preimplantation genetic testing are offered in reproductive centers such as Generate Life Sciences and university-affiliated programs at University of Pennsylvania.

Management and treatment

There is no curative therapy; care is multidisciplinary and centers on cancer surveillance modeled on protocols from National Comprehensive Cancer Network and infection prevention consistent with guidance from World Health Organization. Sun avoidance and use of physical sunscreens are advised following dermatology practices from American Academy of Dermatology. Hematologic malignancies and solid tumors are treated according to oncologic standards at centers including MD Anderson Cancer Center and Dana-Farber Cancer Institute, with consideration of altered chemotherapy sensitivity due to genomic instability described in trials at National Cancer Institute. Immunoglobulin replacement and prophylactic antibiotics follow immunology protocols from American Academy of Allergy, Asthma & Immunology. Reproductive counseling, fertility preservation, and assisted reproductive techniques are coordinated with programs such as those at Cornell University and Stanford University School of Medicine.

Prognosis and complications

Prognosis is guarded because of a markedly increased lifetime risk of multiple malignancies across tissues, including hematologic cancers, gastrointestinal neoplasms, and skin carcinomas treated at tertiary oncology centers like Memorial Sloan Kettering Cancer Center. Complications include chronic obstructive pulmonary disease from recurrent infections managed in respiratory clinics at Royal Brompton Hospital, early-onset type 2 diabetes addressed by American Diabetes Association guidelines, and premature ovarian insufficiency requiring interventions common at University College London Hospitals. Survival has improved with early detection and specialized care offered at comprehensive centers such as Cleveland Clinic and with protocols from the European Society for Medical Oncology.

Epidemiology

Bloom syndrome is rare worldwide but has a higher carrier frequency in the Ashkenazi Jewish population due to documented founder mutations studied by teams at Yale School of Medicine and Tel Aviv University. Case series and registries maintained at institutions like Johns Hopkins Hospital and Children's Hospital of Philadelphia provide the primary epidemiologic data. Incidence estimates vary by region and by ascertainment; population-based surveys informed by projects at Wellcome Trust and public health agencies such as Centers for Disease Control and Prevention continue to refine prevalence figures.

Category:Genetic disorders Category:Rare diseases